Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: A nested case-control study in the CPRD

Osteoporosis International

Volumn 25, Issue 2, 2014, Pages 737-745

  Cooper, C ^a,b,c   Fox, K M ^d   Borer, J S ^e  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

^e SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Cardiac safety; CPRD; Nested case control study; Postmenopausal osteoporosis; Strontiumranelate

Indexed keywords

ALENDRONIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CALCIUM; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STRONTIUM RANELATE; VITAMIN D; BONE DENSITY CONSERVATION AGENT; THIOPHENE DERIVATIVE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; FEMALE; FOLLOW UP; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; OBESITY; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; SMOKING; VITAMIN SUPPLEMENTATION; CHEMICALLY INDUCED; FACTUAL DATABASE; GREAT BRITAIN; MIDDLE AGED; MYOCARDIAL INFARCTION; OSTEOPOROSIS, POSTMENOPAUSAL; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; CASE-CONTROL STUDIES; DATABASES, FACTUAL; FEMALE; GREAT BRITAIN; HOSPITALIZATION; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; OSTEOPOROSIS, POSTMENOPAUSAL; THIOPHENES;

EID: 84897531382     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-013-2582-4     Document Type: Article

References (17)

1. Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459-468 (Pubitemid 38133766)
2. Reginster J-Y, Felsenberg D, Boonen S et al (2008) Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 58:1687-1695 (Pubitemid 351847521)
3. Kaufman JM, Audran M, Bianchi G et al (2013) Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab 98:592-601
4. Reginster JY, Badurski J, Bellamy N et al (2013) Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis 72:179-186
5. Cooper C, Reginster J-Y, Chapurlat R et al (2012) Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of a randomised double-blind, placebo-controlled trial. Curr Med Res Opin 28:231-239
6. European Medicines Agency (2013) PSUR assessment report - strontium ranelate. www.ema.europa.eu. Accessed 27 Aug 2013
7. European Medicines Agency (2006) Summary of product characteristics. Protelos. European Medicines Agency. http://www.ema.europa.eu. Accessed 19 Sept 2013
8. Audran M, Jakob FJ, Palacios S et al (2013) A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years. Rheumatol Int 33:2231-2239
9. Khan NF, Harrison SE, Rose PW (2010) Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 60:e128-e136
10. Herrett E, Thomas SL, Schoonen WM et al (2010) Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 69:4-14
11. Varas-Lorenzo C, Garcia-Rodriguez LA, Perez-Gutthann S et al (2000) Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study. Circulation 101:2572-2578 (Pubitemid 30350634)
12. Hammad TA, McAdams MA, Feight A et al (2008) Determining the predictive value of Read/OXMIS codes to identify incident acute myocardial infarction in the General Practice Research Database. Pharmacoepidemiol Drug Saf 17:1197-1201
13. Mulnier HE, Seaman HE, Raleigh VS et al (2008) Risk ofmyocardial infarction inmen and womenwith type 2 diabetes in the UK: a cohort study using the General Practice Research Database. Diabetologia 51:1639-1645
14. National Institute for Health and Clinical Excellence (2011) Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. NICE technology appraisal guidance TA160. National Institute for Health and Clinical Excellence. www.nice.org.uk/TA160. Accessed 29 Aug 2013
15. Kang JH, Keller JJ, Lin HC (2013) Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study. Osteoporos Int 24:271-277
16. Graham I, Atar D, Borch-Johnsen K et al (2007) European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 28:2375-2414
17. Lampropoulos CE, Papaioannou I, D'Cruz DP (2012) Osteoporosis - a risk factor for cardiovascular disease? Nat Rev Rheumatol 8:587-598